AbbVie’s tavapadon has been approved for adults with Parkinson’s disease by the U.S. Food and Drug Administration (FDA), the U.S. medicines regulator. The once-daily pill will be sold under the brand name Juvmo. Parkinson’s is a long-term brain condition that progressively impairs movement control and can cause tremors, stiffness and balance problems. AbbVie obtained tavapadon through its $8.7 billion acquisition of Cerevel Therapeutics in 2023.